Overexpression of miR-26b decreases the cisplatin-resistance in laryngeal cancer by targeting ATF2
Metrics: PDF 1066 views | HTML 1533 views | ?
Linli Tian1, Jiarui Zhang1, Xiuxia Ren1, Xinyu Liu1, Wei Gao1, Chen Zhang1, Yanan Sun1 and Ming Liu1
1Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China, 150086
Ming Liu, email: email@example.com
Keywords: laryngeal cancer, Hep-2/R, miR-26b, ATF2, cisplatin
Received: July 10, 2017 Accepted: August 09, 2017 Published: September 08, 2017
Cisplatin is a common used chemotherapeutic drug for the treatment of laryngeal cancer. However, drug-resistance is a major obstacle in platinum-based chemotherapy for laryngeal cancer. Recent studies have demonstrated that dysregulation of microRNAs (miRNAs) is responsible for chemoresistance in multiple cancers including laryngeal cancer, but the potential mechanisms are required to be explored. In the present study, we constantly exposed the laryngeal cancer cell line Hep-2 with cisplatin to establish a cisplatin-resistant laryngeal cancer cell model (Hep-2/R). We found that Hep-2/R cells exhibited obvious resistance to cisplatin compared to the Hep-2 cells. However, overexpression of miR-26b significantly decreased the half maximal inhibitory concentration (IC50) of cisplatin to Hep-2/R. Mechanically, miR-26b in Hep-2/R decreased the expression of ATF2, and thus inhibiting the phosphorylation of ATF2 and formation of cellular ATF2-c-Jun complex induced by cisplatin. As the results, Hep-2/R cells failed to overexpress the Bcl-xl which is a key anti-apoptotic protein under the cisplatin treatment. Therefore, overexpression of miR-26b was found to be able to promote mitochondrial apoptosis induced by cisplatin.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.